DENTSPLY SIRONA Inc. (XRAY) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook. While there are positive aspects like innovation investments and strategic plans, there are concerns over declining U.S. sales and unclear timelines for growth. The Q&A section reveals uncertainty in management's responses and lack of clarity on financial impacts, balancing the positive elements. These factors suggest a neutral sentiment, with no strong catalysts for significant stock price movement.
Key Financial Performance
Global Sales $904 million, decreasing 5% as reported or negative 8% on a constant currency basis. Excluding the Byte impact, sales declined 5%. Adjusting for a $24 million onetime dealer prebuy in Q3 '24, sales on a constant currency basis were down 2.5%.
Adjusted EBITDA 18.4%, up 50 basis points versus prior year, driven by lower sales on favorable product and geography mix and tariff impacts that negatively impacted gross profit. This was offset by reduced spending in OpEx.
Non-GAAP Earnings Per Share $0.37, down $0.13 versus prior year. Approximately half the EPS decline reflects the impacts of sales mix and tariffs on gross profit, with the remaining half driven by higher non-GAAP tax rates in the quarter of 32% versus 16% last year.
Cash from Operations $79 million, with an ending cash balance of $363 million.
Noncash After-Tax Charge $263 million related to the impairment of goodwill and intangible assets, driven by the impacts of tariffs and lower projected volumes of equipment, implants, and prosthetic products, particularly in the U.S.
Shareholder Returns $32 million returned to shareholders through dividends in Q3, with $96 million returned year-to-date.
U.S. Sales $291 million, down 22.2% versus prior year, driven by lower sales throughout Essential Dental Solutions, CAD/CAM, Imaging, and Implants, partially offset by strong performance in treatment centers and Wellspect business, which delivered 22.3% growth. Adjusting for the Byte impact and the onetime $24 million prior year, U.S. sales were down 9.7%.
European Sales $382 million, increasing 9.9% as reported or 2.6% on a constant currency basis, driven by growth in Connected Technology Solutions and Labs, partially offset by softness in restorative. Wellspect sales grew 5.3% in Europe on a constant currency basis.
Rest of World Sales $231 million, down slightly versus prior year, with strength in Essential Dental Solutions offset by declines in Connected Technology Solutions and Implants. Wellspect grew 87.3% off a small base in Q3.
CTS Sales Decreased 7% on a constant currency basis versus prior year. Equipment & Instruments increased by low single digits, reflecting growth of Imaging in Europe and Rest of World and growth of treatment centers across all 3 regions, partially offset by a decline in Imaging in the U.S. E&I growth was offset by a double-digit decline from CAD/CAM in the U.S. and Rest of World.
EDS Sales Decreased 6.2% on a constant currency basis, with the decline entirely attributed to the previously described dealer prebuy.
OIS Sales Declined 17.1% on a constant currency basis. Excluding the Byte impact, OIS sales were down 5.8%. SureSmile declined low single digits in the quarter, partially offset by growth in Europe and Rest of World. IPS declined mid-single digits, driven by lower implant volumes in the U.S. and China, with a slowdown in the Chinese market in anticipation of the implementation of the second phase of the VBP program. In Europe, IPS increased slightly.
Wellspect Healthcare Sales Increased 9.3% on a constant currency basis, with growth across all 3 regions.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Wellspect Business: The Wellspect business demonstrated significant growth, with a 22.3% increase in the U.S. and 87.3% growth in Rest of World. The company has decided to retain this business for its strong cash flow generation and potential for future growth beyond dental.
Regional Sales Performance: U.S. sales declined by 22.2%, driven by lower sales in Essential Dental Solutions, CAD/CAM, Imaging, and Implants. European sales increased by 9.9%, with strong growth in the U.K., France, Italy, and Spain. Rest of World sales were slightly down, with strength in Australia and India offset by softness in Japan.
Operational Efficiencies: The company is focusing on resource consolidation, standardized packaging, and advanced planning to improve working capital and product costs. It is also implementing SAP as a global ERP system to streamline operations.
Return-to-Growth Action Plan: The company introduced a 24-month plan focusing on four pillars: putting customers at the center, reigniting the U.S. business, empowering people, and evolving operations to fuel innovation. Specific actions include creating a global customer service organization, reorganizing commercial teams, and increasing investments in clinical education and R&D.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Performance: Global sales decreased by 5% as reported or 8% on a constant currency basis. U.S. sales were down 22.2%, driven by lower sales in key segments like Essential Dental Solutions, CAD/CAM, Imaging, and Implants. Adjusted EPS declined due to unfavorable sales mix, tariffs, and higher tax rates. A $263 million noncash charge was recorded due to goodwill and intangible asset impairments.
Tariff Impacts: Tariffs negatively impacted gross profit and contributed to the impairment of goodwill and intangible assets. This has also led to lower projected volumes of equipment, implants, and prosthetic products, particularly in the U.S.
U.S. Market Challenges: The U.S. market experienced significant declines in sales across multiple segments, including CAD/CAM and Imaging. Distributor inventory levels for these products remain below historical averages, indicating potential supply chain or demand issues.
Chinese Market Slowdown: A slowdown in the Chinese market was observed due to the anticipation of the second phase of the VBP program, which impacted implant volumes.
Leadership and Organizational Changes: The departure of the CFO and ongoing search for a replacement may create temporary instability in financial leadership. Additionally, the company is undergoing significant organizational restructuring, which could disrupt operations in the short term.
Operational Efficiency: Efforts to streamline operations, including resource consolidation and SAP implementation, may face execution risks. The need to reduce complexity and optimize resources could strain existing systems and processes.
Regulatory and Competitive Pressures: The company faces competitive pressures in the U.S. and regulatory challenges in markets like China, which could hinder growth and market penetration.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Financial Outlook: The company revised its 2025 outlook, projecting net sales in the range of $3.6 billion to $3.7 billion, with constant currency sales expected to decline by 4% to 5% year-over-year. Adjusted EPS is anticipated to be approximately $1.60.
Growth Momentum in 2026: Targeted investments are being made to accelerate growth momentum in 2026, including regional investments in EMEA and Asia Pacific.
Return-to-Growth Action Plan: The company aims to deliver sustained profitable growth over the next 24 months through four key pillars: putting customers at the center, reigniting the U.S. business, empowering people to power performance, and evolving operations to fuel innovation.
U.S. Business Reignition: A comprehensive plan is in place to reignite growth in the U.S. market, including aligning commercial teams, expanding sales coverage, and increasing investments in clinical education and sales training.
Global Customer Service Enhancements: Plans to create a global customer service and technical service organization to deliver high-quality support worldwide, with a focus on agility to meet local market needs.
Innovation and R&D Investments: The company plans to increase and accelerate R&D investments to enhance care, streamline workflows, and grow practices, while also improving the health of its commercial engine.
Operational Efficiency Improvements: Steps are being taken to enhance operational efficiencies through resource consolidation, standardized packaging, advanced planning, and forecasting to improve working capital and product costs.
Wellspect Business Strategy: The company has decided to retain the Wellspect business, leveraging its strong cash flow generation and preserving optionality for future growth beyond dental.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends returned in Q3 2025: $32 million
Year-to-date dividends returned: $96 million
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk more about the U.S. market and the factors driving the year-over-year decline?
A:The decline is attributed to multiple factors, including the structural approach, execution in the U.S. market, relationships with dealers, and strategies with DSOs. The focus is on addressing shortcomings through the 'return to health' plan, improving structure, funding, and execution.
Q:How should we think about the cadence of returning to profitable growth over the next 24 months?
A:The CEO emphasized the need for more time to refine the plan. Sequential improvements are expected throughout the year, but specific timing for growth is not yet determined. The goal is to achieve growth, but it won't happen immediately.
Q:What is your philosophy around capital allocation, specifically regarding dividends?
A:The focus is on deleveraging by retiring debt and growing the business, particularly in the U.S. and globally, to raise EBITDA. The dividend's importance in shareholder value will be explored further with the Board and shareholders.
Q:Can you elaborate on the R&D aspect of the Return-to-Growth action plan?
A:Millions of dollars in R&D investment are being pulled forward into Q4 to strengthen the position for 2026 and beyond. The goal is to increase R&D spending to 6-7% of sales, ensuring efficient spending and risk mitigation.
Q:Should we expect a new run rate for OpEx spending based on the guidance adjustment?
A:The CEO clarified that the increased spending is a temporary measure to jump-start investments. Efficiencies will be found to make the spending self-funding over time, with a focus on increasing EBITDA and reducing OpEx in the long term.
Q:What is your view of the European and international markets?
A:The European market shows signs of improvement, attributed to strong leadership and resource organization. Surveys indicate no drastic shifts in the international market, and the approach in Europe is being considered for application in the U.S.
Q:How are you thinking about your relationship with distributors and the supply chain?
A:The company is adopting a multichannel approach, maintaining direct businesses while reengaging with dealers like Schein and Patterson. Discussions with new dealers are ongoing, and the goal is to finalize these strategies by next year.
Q:What are the key milestones for measuring success in the Return-to-Growth action plan?
A:Key milestones include stabilizing and growing U.S. sales, hiring and retaining reps, increasing training for reps and clinical partners, improving presence in universities, and achieving gross profit lifts through supply chain improvements and R&D product launches.
Q:What impact do you expect from the appointment of Aldo Denti as Chief Commercial Officer?
A:Aldo Denti brings experience in turnarounds and commercial leadership. His focus will be on creating a well-resourced commercial team, improving dealer and DSO relationships, and driving growth through professional and focused strategies.
Q:Which areas of the business are best positioned to stabilize growth?
A:All areas require different approaches. Key focuses include improving customer service and technical service, enhancing implant strategies, leveraging DS Core, and ensuring balanced investments across the portfolio.
Q:What characteristics are you looking for in a new CFO, and how might guidance philosophy change?
A:The new CFO should have strong data analysis and communication skills, with a focus on driving metrics and strategy. The guidance philosophy will aim for conservative estimates with the goal of beating and raising expectations.
Q:What specific investments are being made in Q4, and what should we expect in 2026?
A:Q4 investments include R&D acceleration, preparation for clinical education programs, and contractual moves to free up cash for strategic initiatives. Customer service and tech service changes will have more impact in 2026.
Q:What initiatives in the Return-to-Growth plan are incremental compared to past efforts?
A:The CEO emphasized a deeper, faster, and bolder approach compared to past efforts, focusing on execution and measurable results rather than just plans and discussions.
Q:What are the pain points in the Implants business, and how will they be addressed?
A:Pain points include insufficient reps, inadequate training, and lack of branding coordination. The plan involves increasing training for reps and dentists, leveraging DS Core, and ensuring a stronger presence in the market.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or detailed metrics for returning to growth, particularly regarding the cadence of improvements over the next 24 months. Additionally, there was a lack of clarity on the exact financial impact of Q4 investments and the specifics of dealer reengagement strategies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Conference Instructions
DENTSPLY SIRONA
Form SEC
Instructions today
Officer press
President Chief
Relations moment
SIRONA Conference
SIRONA today
conference speaker
day DENTSPLY
filing DENTSPLY
information Form
speaker today
today Investor
today President
website wwwdentsplysironacom
wwwdentsplysironacom risk
XRAY Transcript
DENTSPLY SIRONA Inc. (XRAY) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Neutral5-27
DENTSPLY SIRONA Inc. (XRAY) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call reveals mixed signals: strong product sales and EMEA growth, but weak guidance and margin contraction. The restructuring plan shows potential, but its benefits are long-term. Eliminating dividends for debt reduction and share repurchases is neutral. Unclear management responses in Q&A raise concerns. These factors balance out, suggesting a neutral stock price movement in the short term.
DENTSPLY SIRONA Inc. (XRAY) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
DENTSPLY SIRONA Inc. (XRAY) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call summary presents a mixed outlook: while there are positive elements such as strategic investments, operational improvements, and a favorable agreement with Patterson, there are also concerns about declining sales and unclear management responses on key issues like free cash flow and new product launches. The Q&A section reveals optimism for future growth but also highlights uncertainties, particularly with regulatory approvals and market penetration strategies. Given the absence of a market cap, the predicted stock movement is neutral, reflecting both potential growth and existing challenges.
XRAY Slides
Dentsply Sirona Q4 2025 slides: revenue beats amid restructuring push2026-02-26
Dentsply Sirona Q3 2025 slides: Sales decline despite margin gains, stock falls 12%2025-11-06
Dentsply Sirona Q2 2025 slides: Sales decline offset by margin expansion under new leadership2025-08-07
Dentsply Sirona Q1 2025 slides: Margin expansion offsets continued sales decline2025-05-08
XRAY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
